SAB Biotherapeutics (SABS)
(Delayed Data from NSDQ)
$2.78 USD
+0.08 (2.79%)
Updated Jul 31, 2024 12:22 PM ET
After-Market: $2.84 +0.06 (2.33%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SABS 2.78 +0.08(2.79%)
Will SABS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SABS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SABS
Here's Why SAB Biotherapeutics, Inc. (SABS) Is a Great 'Buy the Bottom' Stock Now
Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates
SABS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Illumina (ILMN) Beats Q1 Earnings and Revenue Estimates
SAB Biotherapeutics, Inc. (SABS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Other News for SABS
SAB Biotherapeutics Announces Key Executive Appointment
SAB BIO Appoints Lucy To as Chief Financial Officer
SAB Biotherapeutics names Lucy To as CFO
SAB Biotherapeutics appoints Lucy To as Chief Financial Officer
SAB Biotherapeutics management to meet with Oppenheimer